Fezolinetant
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications
TACR3 variant confers resilience to aging and Alzheimer's disease.
Journal: medRxiv : the preprint server for health sciences
Published: June 22, 2026
Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause.
Journal: Climacteric : the journal of the International Menopause Society
Published: May 20, 2026
Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study.
Journal: Women's health (London, England)
Published: April 03, 2026
Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms?
Journal: JAAPA : official journal of the American Academy of Physician Assistants
Published: March 24, 2026
Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant.
Journal: Breast (Edinburgh, Scotland)
Published: February 09, 2026
Hepatic Adverse Event Signals of Fezolinetant in Real-World Use Based on Postmarketing Surveillance.
Hepatic Adverse Event Signals of Fezolinetant in Real-World Use Based on Postmarketing Surveillance.
Journal: Obstetrics and gynecology
Published: January 22, 2026
Expression of Concern: Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-Analysis.
Journal: Obstetrics and gynecology
Published: January 15, 2026
Elinzanetant (Lynkuet) for menopausal vasomotor symptoms.
Journal: The Medical letter on drugs and therapeutics
Published: December 15, 2025
Elinzanetant: Defining the Role of Dual Neurokinin-1 and Neurokinin-3 Receptor Antagonism for Management of Vasomotor Symptoms in Menopause.
Journal: Journal of menopausal medicine
Published: December 12, 2025
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.
Journal: Journal of the Endocrine Society
Published: November 27, 2025
Clinical Pharmacokinetics, Mass Balance and Metabolism of Fezolinetant in Postmenopausal Women.
Journal: European journal of drug metabolism and pharmacokinetics
Published: October 31, 2025
Repurposing sulfonamide drugs as anticancer ligands and understanding its properties through density functional theory.
Journal: Computational biology and chemistry
Published: October 25, 2025
Last Updated: 06/30/2026